<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068466</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54707-108</org_study_id>
    <nct_id>NCT05068466</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Biosciences Japan GK</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled, sponsor-unblinded,&#xD;
      Phase 1 study designed to evaluate the safety, tolerability, and PK of escalating oral doses&#xD;
      of INCB054707 in healthy male Japanese participants. Participants in each cohort will be&#xD;
      divided into placebo or INCB054707 by a 3:1 INCB054707:placebo random assignment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Treatment Emergent Adverse Events (TEAE'S)</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter : Cmax of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Maximum Observed Plasma Concentration of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter : Cmin of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Minimum Observed Plasma Concentration of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter : tmax of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Time to reach maximum plasma concentration of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter : AUC(0-t) of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Area Under the concentration- time curve up to the last measurable concentration of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter : AUC(0-∞) of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Area Under the Concentration-time Curve From 0 to Infinity of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter : AUC(0-tau) of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Area under the single-dose or steady-state plasma concentration-time curve from hour 0 to the end of the dosing period of INCB054707</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : t1/2 of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics Parameter : t1/2 of Apparent terminal phase disposition half-life of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : CL/F of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Oral dose clearance of INCB054707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : Vz/F of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Apparent oral dose volume of distribution of INCB54707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : Cavg of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Average plasma concentration at steady state of INCB054707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : λz of INCB054707</measure>
    <time_frame>17 Days</time_frame>
    <description>Apparent terminal-phase disposition rate constant of INCB054707</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>INCB054707 (Dose A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered single-dose INCB054707 on Day 1 followed by once daily dose of INCB054707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB054707 (Dose B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single-dose INCB054707 on Day 1 followed by once daily dose of INCB54707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Dose A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Dose B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054707</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>INCB054707 (Dose A)</arm_group_label>
    <arm_group_label>INCB054707 (Dose B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Placebo (Dose A)</arm_group_label>
    <arm_group_label>Placebo (Dose B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male healthy Japanese adult participants aged 20 to 55 years with a minimum weight of&#xD;
             48 kg.&#xD;
&#xD;
          -  Body mass index between 18.0 and 30.5 kg/m2.&#xD;
&#xD;
          -  No clinically significant findings in screening evaluations.&#xD;
&#xD;
          -  Ability to swallow and retain oral medication.&#xD;
&#xD;
          -  Willingness to avoid fathering children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant cardiovascular, respiratory, renal,&#xD;
             gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease.&#xD;
&#xD;
          -  History of rheumatologic/autoimmune disorders, except for minor eczema and rosacea.&#xD;
&#xD;
          -  Resting pulse &lt; 40 bpm or &gt; 100 bpm, confirmed by repeat testing at screening.&#xD;
&#xD;
          -  History or presence of an abnormal ECG before initial dose administration that, in the&#xD;
             investigator's opinion, is clinically significant.&#xD;
&#xD;
          -  Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's&#xD;
             disease or chronic pancreatitis).&#xD;
&#xD;
          -  Hemoglobin, WBC, platelet, or ANC that is out of the laboratory's range unless&#xD;
             considered clinically insignificant by the investigator at screening or check-in.&#xD;
&#xD;
          -  History of malignancy within 5 years of screening, with the exception of cured basal&#xD;
             cell or squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Current or recent (within 6 months of screening) clinically significant&#xD;
             gastrointestinal disease or surgery (including cholecystectomy, excluding&#xD;
             appendectomy) that could affect the absorption of study drug.&#xD;
&#xD;
          -  Any major surgery within 6 months of screening.&#xD;
&#xD;
          -  Donation of blood to a blood bank or in a clinical study (except a screening visit)&#xD;
             within 4 weeks of screening (within 2 weeks for plasma donation).&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of check-in.&#xD;
&#xD;
          -  Chronic or current active infectious disease requiring systemic antibiotic,&#xD;
             antifungal, or antiviral treatment&#xD;
&#xD;
          -  Positive test for HIV and known active HBV or HCV infection or risk of reactivation of&#xD;
             HBV or HCV.&#xD;
&#xD;
          -  History of alcoholism within 3 months of screening.&#xD;
&#xD;
          -  Positive breath or urine test for ethanol or positive urine screen for drugs of abuse&#xD;
             that are not otherwise explained by permitted concomitant medications or diet.&#xD;
&#xD;
          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer)&#xD;
             before the first dose of study drug with another investigational medication or current&#xD;
             enrollment in another investigational drug study.&#xD;
&#xD;
          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer)&#xD;
             before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or&#xD;
             BCRP&#xD;
&#xD;
          -  Current use of prohibited medication&#xD;
&#xD;
          -  Consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus&#xD;
             fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed&#xD;
             clinically relevant by the investigator.&#xD;
&#xD;
          -  Known hypersensitivity or severe reaction to INCB054707 or any excipients of&#xD;
             INCB054707&#xD;
&#xD;
          -  Inability to undergo venipuncture or tolerate venous access.&#xD;
&#xD;
          -  Inability or unlikeliness of the participant to comply with the dose schedule and&#xD;
             study evaluations, in the opinion of the investigator.&#xD;
&#xD;
          -  History of tobacco- or nicotine-containing product use within 1 month of screening.&#xD;
&#xD;
          -  Use of prescription drugs within 14 days of study drug administration or&#xD;
             nonprescription medications/products within 7 days of study drug administration.&#xD;
&#xD;
          -  Any condition that would, in the investigator's judgment, interfere with full&#xD;
             participation in the study.&#xD;
&#xD;
          -  Positive syphilis test.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Biosciences Japan GK Development Operations Call Center (US)</last_name>
    <phone>+81 3-3507-5795</phone>
    <email>japan_clinicaltrials@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigative Site 001</name>
      <address>
        <city>Fukuoka</city>
        <zip>8130017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INCB054707</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

